Insider · CIK 0001907199
Cintia Piccina
Files at ADAPY (Adaptimmune Therapeutics PLC), AUTL (Autolus Therapeutics plc). First filing Jan 15, 2025, latest Sep 3, 2026.
Cintia Piccina files SEC Form 4 as officer at ADAPY (Adaptimmune Therapeutics PLC), and also at AUTL (Autolus Therapeutics plc). Since Jan 15, 2025, Cintia Piccina has reported 0 open-market buys worth $0 and 2 open-market sells worth $23k, the latest filed on Sep 3, 2026.
A track record needs three past buys with six months of prices behind them; Cintia Piccina has 0, so none is measured yet.
The newest scored trade: sold $16k of AUTL on Sep 2, 2026, filed Sep 3, 2026, scored 10 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $16k.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
AUTL: Autolus Therapeutics plc
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
ADAPY: Adaptimmune Therapeutics PLC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | AUTLsell Autolus Therapeutics plc | $16k 6,713 shares | -34% | - | |
| 40Moderate | Adaptimmune Therapeutics PLC | $7,467 12,991 shares | -41% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 15, 2025 | ADAPY Adaptimmune Therapeutics PLC | 12,991 0.01% of outstanding | $7,467 | Jan 15, 2025 | none |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | AUTL Autolus Therapeutics plc | MOption exercise American Depositary Shares | +20,000 | $2.35 | $47k | 20,000 | 40 d ago |
| Sep 2, 2026 | AUTL Autolus Therapeutics plc | SOpen-market sale American Depositary Shares | -6,713 | $2.34 | $16k | 13,287 | 40 d ago |
| Sep 1, 2026 | AUTL Autolus Therapeutics plc | MOption exercise Restricted Share Unitsderivative | -20,000 | $0.00 | $0 | 60,000 | 40 d ago |
| Feb 20, 2025 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to purchase Ordinary Sharesderivative | +1,612,032 | $0.00 | $0 | 1,612,032 | Feb 20, 2025 |
| Feb 20, 2025 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to purchase Ordinary Sharesderivative | +1,074,696 | $0.00 | $0 | 1,074,696 | Feb 20, 2025 |
| Jan 15, 2025 | ADAPY Adaptimmune Therapeutics PLC | SOpen-market sale American Depositary Shares representing Ordinary Shares | -12,991 | $0.57 | $7,467 | 18,421 | Jan 15, 2025 |
Questions about Cintia Piccina
Answered from the filings on this page, as of the latest one.
Is Cintia Piccina buying or selling?
In the last 12 months Cintia Piccina reported 0 open-market buys worth $0 and 1 open-market sell worth $16k on SEC Form 4; the latest was sold $16k of AUTL on Sep 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Cintia Piccina's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Cintia Piccina has 0.
Where does Cintia Piccina file Form 4?
Cintia Piccina has filed Form 4 at ADAPY (Adaptimmune Therapeutics PLC) as Chief Commercial Officer; AUTL (Autolus Therapeutics plc) as U.S. CCO & Country Gen Manager. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.